Company: INDP
Filing Date: 2025-03-27
Form Type: DRS
Source: 0001641172-25-000975
Chunk: 33

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-27
Form: DRS
Chunk 33
---
 various laws such as the Foreign Corrupt Practices Act; and                                     |

| 18 |

| ● | covenants regarding matters                                                                                                                  
 such as registration of warrant shares, no integration with other offerings, no stockholder rights plans, no material nonpublic information, 
 use of proceeds, indemnification of purchasers, reservation and listing of shares of common stock, no subsequent equity sales for          , 
 subject to certain exceptions, and an agreement to not enter into variable rate financings for                                               
 from closing, subject to certain exceptions.                                                                                                 |

The securities will be offered at a fixed price and are expected to be issued in a single closing. We expect this offering to be completed not later than one business day following the commencement of this offering, which will be the date that we enter into a securities purchase agreement to sell the securities offered hereby. We expect to close the offering on or before , 2025. We will deliver all securities to be issued in connection with this offering delivery versus payment/receipt versus payment upon receipt of investor funds received by us. Accordingly, neither we nor the Placement Agent have made any arrangements to place investor funds in an escrow account or trust account since the Placement Agent will not receive investor funds in connection with the sale of the securities offered hereunder.

We expect to deliver the shares of common stock, pre-funded warrants and common warrants being offered pursuant to this prospectus on or about , 2025.

Fees and Expenses

The following table shows the per share and accompanying common warrant and per pre-funded warrant and accompanying common warrant and total placement agent fees we will pay in connection with the sale of the securities in this offering.

|                                 |     | Per Share and       
 Accompanying Common 
 Warrant             |     | Per                             
 Pre-Funded                      
 Warrant and Accompanying Common 
 Warrant                         |     | Total |
| Combined public offering price  |     |                     |     |                                 |     |       |
| Placement agent fees            |     |                     |     |                                 |     |       |
| Proceeds to us, before expenses |     |                     |     |                                 |     |       |

We have agreed to pay the Placement Agent a cash fee equal to % of the aggregate gross proceeds raised in this offering and a management fee equal to % of the gross proceeds raised in this offering. In addition, we have agreed to reimburse the Placement Agent $ for its non-accountable expenses and up to $ for legal fees and out-of-pocket expenses and for its clearing expenses in the amount